{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:51:43Z","timestamp":1784735503745,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13550-019-0530-9","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T13:02:53Z","timestamp":1564491773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-371X","authenticated-orcid":false,"given":"Kamil G.","family":"Laban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos J.","family":"Leguit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"de Keizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"530_CR1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ophtha.2003.01.002","volume":"111","author":"JA Shields","year":"2004","unstructured":"Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 Montgomery lecture, part 1. Ophthalmology. 2004;111:997\u20131008.","journal-title":"Ophthalmology"},{"key":"530_CR2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/sj.eye.6702383","volume":"20","author":"LK Gordon","year":"2006","unstructured":"Gordon LK. Orbital inflammatory disease: a diagnostic and therapeutic challenge. Eye. 2006;20:1196\u2013206.","journal-title":"Eye"},{"key":"530_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.survophthal.2016.03.002","volume":"61","author":"I Mombaerts","year":"2016","unstructured":"Mombaerts I, Rose GE, Garrity JA. Orbital inflammation: biopsy first. Surv Ophthalmol. 2016;61:664\u20139.","journal-title":"Surv Ophthalmol"},{"key":"530_CR4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.survophthal.2016.01.005","volume":"61","author":"LR Dagi Glass","year":"2016","unstructured":"Dagi Glass LR, Freitag SK. Orbital inflammation: corticosteroids first. Surv Ophthalmol. 2016;61:670\u20133.","journal-title":"Surv Ophthalmol"},{"key":"530_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13075-016-1166-z","volume":"18","author":"S Bruijnen","year":"2016","unstructured":"Bruijnen S, Tsang-A-Sjoe M, Raterman H, Ramwadhdoebe T, Vugts D, van Dongen G, et al. B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients. Arthritis Res Ther. 2016;18:266.","journal-title":"Arthritis Res Ther"},{"key":"530_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ajh.24328","volume":"91","author":"A de Jong","year":"2016","unstructured":"de Jong A, Mous R, van Dongen GAMS, Hoekstra OS, Nievelstein RAJ, de Keizer B. (89) Zr-rituximab PET\/CT to detect neurolymphomatosis. Am J Hematol. 2016;91:649\u201350.","journal-title":"Am J Hematol"},{"key":"530_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00259-015-3025-6","volume":"42","author":"K Muylle","year":"2015","unstructured":"Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, et al. Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging. 2015;42:1304\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"530_CR8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/jamaophthalmol.2013.8179","volume":"132","author":"EB Suhler","year":"2014","unstructured":"Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, et al. Rituximab therapy for refractory orbital inflammation: results of a phase 1\/2, dose-ranging, randomized clinical trial. JAMA Ophthalmol. 2014;132:572\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"530_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamaophthalmol.2017.1581","volume":"135","author":"I Mombaerts","year":"2017","unstructured":"Mombaerts I, Bilyk JR, Rose GE, McNab AA, Fay A, Dolman PJ, et al. Consensus on diagnostic criteria of idiopathic orbital inflammation using a modified Delphi approach. JAMA Ophthalmol. 2017;135:769\u201376.","journal-title":"JAMA Ophthalmol."},{"key":"530_CR10","first-page":"1271","volume":"44","author":"I Verel","year":"2003","unstructured":"Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271\u201381.","journal-title":"J Nucl Med"},{"key":"530_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"530_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/01676830.2014.959185","volume":"34","author":"A Klingenstein","year":"2015","unstructured":"Klingenstein A, Haug AR, Miller C, Hintschich C. Ga-68-DOTA-TATE PET\/CT for discrimination of tumors of the optic pathway. Orbit. 2015;34:16\u201322.","journal-title":"Orbit"},{"key":"530_CR13","doi-asserted-by":"publisher","first-page":"e0169828","DOI":"10.1371\/journal.pone.0169828","volume":"12","author":"YWS Jauw","year":"2017","unstructured":"Jauw YWS, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, et al. Performance of 89Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed\/refractory diffuse large B cell lymphoma. PLoS One. 2017;12:e0169828 Glod JW, editor.","journal-title":"PLoS One"},{"key":"530_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/1352458517704507","volume":"24","author":"MH Hagens","year":"2018","unstructured":"Hagens MH, Killestein J, Yaqub MM, van Dongen GA, Lammertsma AA, Barkhof F, et al. Cerebral rituximab uptake in multiple sclerosis: A 89 Zr-immunoPET pilot study. Mult Scler J. 2018;24:543\u20135.","journal-title":"Mult Scler J"},{"key":"530_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/HAB-2011-0239","volume":"20","author":"L Tran","year":"2011","unstructured":"Tran L, Huitema ADR, van Rijswijk MH, Dinant HJ, Baars JW, Beijnen JH, et al. CD20 antigen imaging with 124I-rituximab PET\/CT in patients with rheumatoid arthritis. Hum Antibodies. 2011;20:29\u201335.","journal-title":"Hum Antibodies"},{"key":"530_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s11307-011-0527-x","volume":"14","author":"G Malviya","year":"2012","unstructured":"Malviya G, Anzola KL, Podest\u00e0 E, Lagan\u00e0 B, Del Mastro C, Dierckx RA, et al. (99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients. Mol Imaging Biol. 2012;14:637\u201346.","journal-title":"Mol Imaging Biol"},{"key":"530_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s13277-012-0316-4","volume":"33","author":"GAMS van Dongen","year":"2012","unstructured":"van Dongen GAMS, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012;33:607\u201315 Springer.","journal-title":"Tumour Biol"},{"key":"530_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fphar.2016.00131","volume":"7","author":"YWS Jauw","year":"2016","unstructured":"Jauw YWS, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, et al. Immuno-positron emission tomography with Zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? Front Pharmacol. 2016;7:131 Frontiers Media SA.","journal-title":"Front Pharmacol"},{"key":"530_CR19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.otc.2006.07.003","volume":"39","author":"JB Chastain","year":"2006","unstructured":"Chastain JB, Sindwani R. Anatomy of the orbit, lacrimal apparatus, and lateral nasal wall. Otolaryngol Clin N Am. 2006;39:855\u201364.","journal-title":"Otolaryngol Clin N Am"},{"key":"530_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00330-017-4995-5","volume":"28","author":"A Hiwatashi","year":"2018","unstructured":"Hiwatashi A, Togao O, Yamashita K, Kikuchi K, Kamei R, Yoshikawa H, et al. Diffusivity of intraorbital lymphoma vs. inflammation: comparison of single shot turbo spin echo and multishot echo planar imaging techniques. Eur Radiol. 2018;28:325\u201330.","journal-title":"Eur Radiol"},{"key":"530_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3109\/09273948.2013.863943","volume":"23","author":"RG Abell","year":"2015","unstructured":"Abell RG, Patrick A, Rooney KG, McKelvie PA, McNab AA. Complete resolution of idiopathic sclerosing orbital inflammation after treatment with rituximab. Ocul Immunol Inflamm. 2015;23:176\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"530_CR22","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/S0161-6420(96)30378-3","volume":"103","author":"I Mombaerts","year":"1996","unstructured":"Mombaerts I, Schlingemann RO, Goldschmeding R, Koornneef L. Idiopathic granulomatous orbital inflammation. Ophthalmology. 1996;103:2135\u201341.","journal-title":"Ophthalmology"},{"key":"530_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100:432\u201341.","journal-title":"J Clin Endocrinol Metab"},{"key":"530_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"530_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","volume":"117","author":"D Khanna","year":"2010","unstructured":"Khanna D, Chong KKL, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2010;117:133\u2013139.e2.","journal-title":"Ophthalmology"},{"key":"530_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/IOP.0b013e3181c4dfde","volume":"26","author":"RZ Silkiss","year":"2010","unstructured":"Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2010;26:310\u20134.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"530_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/thy.2006.16.709","volume":"16","author":"D El Fassi","year":"2006","unstructured":"El Fassi D, Nielsen CH, Hasselbalch HC, Heged\u00fcs L. Treatment-resistant severe, active graves\u2019 ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 2006;16:709\u201310.","journal-title":"Thyroid"},{"key":"530_CR28","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1530\/EJE-16-0552","volume":"176","author":"MN Stan","year":"2017","unstructured":"Stan MN, Salvi M. MANAGEMENT OF ENDOCRINE DISEASE: rituximab therapy for Graves\u2019 orbitopathy\u2014lessons from randomized control trials. Eur J Endocrinol. 2017;176:R101\u20139.","journal-title":"Eur J Endocrinol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0530-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13550-019-0530-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0530-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T23:04:26Z","timestamp":1595977466000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-019-0530-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1186\/s13550-019-0530-9","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]},"assertion":[{"value":"13 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We performed this study in compliance with the 1964 Helsinki Declaration and its later amendments and federal laws in the Netherlands and the European Union. Following review of the study design and protocol, the local Medical Research Ethical Committee (MREC)(Medisch Ethische Toetsingscommissie Utrecht) confirmed that the Medical Research Involving Human Subjects Act (WMO) does not apply to this study and that therefore an official approval of this study by the local MREC is not required under the WMO (protocol number: 18\u2013120). All patients signed written informed consent for participation in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed written informed consent for the use of their data in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}